The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Konverge Plus 40mg/5mg/25mg film coated tablets



Menarini International Operations Luxembourg S.A.PA0865/019/004

Main Information

Trade NameKonverge Plus 40mg/5mg/25mg film coated tablets
Active SubstancesOlmesartan medoxomil
Amlodipine
Hydrochlorothiazide
Dosage FormFilm-coated tablet
Licence HolderMenarini International Operations Luxembourg S.A.
Licence NumberPA0865/019/004

Group Information

ATC CodeC09DX Angiotensin II antagonists, other combinations
C09DX03 olmesartan medoxomil, amlodipine and hydrochlorothiazide

Status

License statusAuthorised
Licence Issued23/09/2011
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back